Leukemia, Myeloid, Acute: all 3,035 studies
Page 29 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Intermittent Liposomal Amphotericin B Primary ProphylaxisStatus unknownNCT00451711Phase 2
- AML Treatment in Untreated Adult PatientsStatus unknownNCT00449319Not applicable
- A Phase II Study of Maintenance With Azacitidine in MDS PatientsTerminatedNCT00446303Phase 2
- Effectiveness of Protected Environment Rooms for AML and MDSTerminatedNCT00443300
- Natural Killer Index From Hematopoietic Stem Cell GraftCompletedNCT00435864Not applicable
- Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AMLTerminatedNCT00430443Phase 1
- Timed-Sequential Induction in CBF-AMLCompletedNCT00428558Phase 3
- Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing ChemotherapyCompletedNCT00413439Phase 2/3
- Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid LeukemiaCompletedNCT00401739Phase 1
- A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous LeukemiaCompletedNCT00400673Phase 2
- AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDSWithdrawnNCT00396968Phase 1/2
- Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00394381Phase 1/2
- Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingNCT00392353Phase 1/2
- Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary AspergillosisCompletedNCT00391014Phase 2
- Treatment of Acute Myeloblastic Leukemia in Younger PatientsCompletedNCT00390715
- Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseCompletedNCT00383474Phase 1
- Phase I Using Velcade & Idarubicin in Elderly and Relapsed AMLCompletedNCT00382954Phase 1
- Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell TransplantationCompletedNCT00374933Phase 1
- MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2
- Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AMLCompletedNCT00373373Phase 2
- A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.TerminatedNCT00363025Phase 3
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.CompletedNCT00354146Phase 2
- Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic TransplantCompletedNCT00354120Phase 2/3
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid LeukemiaCompletedNCT00342316Not applicable
- 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDSCompletedNCT00339196Phase 2
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic SyndromesSuspendedNCT00329498Phase 2
- A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2
- Study of XL999 in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT00322673Phase 2
- AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous LeukemiaCompletedNCT00321581Phase 1
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
- Study of Bexarotene in Patients With Acute Myeloid LeukemiaCompletedNCT00316030Phase 1
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family DonorStatus unknownNCT00304720Phase 2
- Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
- Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.CompletedNCT00299780Phase 1
- A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction TherapyWithdrawnNCT00297921Phase 1/2
- Use of the MiCK Assay for Apoptosis in AMLCompletedNCT00286845
- Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)CompletedNCT00285259Phase 2
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00283114Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid LeukemiaTerminatedNCT00279773Phase 1
- Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous LeukemiaCompletedNCT00274248Phase 1
- Amonafide in Combination With Cytarabine in Secondary AMLCompletedNCT00273884Phase 2
- Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic MalignanciesCompletedNCT00270881Phase 1/2
- Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)CompletedNCT00266136Phase 3
- Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory LeukemiaCompletedNCT00251368Phase 1
- Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic MalignanciesCompletedNCT00246662Phase 1
- T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)Status unknownNCT00242515Phase 1/2
- Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia PatientsCompletedNCT00235560Phase 2
- A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaCompletedNCT00233909Phase 1/2
- Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid LeukaemiaStatus unknownNCT00224614Phase 3
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
- Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-TStatus unknownNCT00209833Phase 2/3
- Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
- Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)CompletedNCT00188136Phase 2
- Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00186966Phase 3
- Haploidentical Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00186823Phase 3
- Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent RemissionCompletedNCT00186381Phase 2
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)TerminatedNCT00185523
- Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraCCompletedNCT00180167Phase 4
- AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia PatientsCompletedNCT00180115Phase 4
- AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 YearsCompletedNCT00180102Phase 4
- Differentiation Induction in Acute Myelogenous LeukemiaCompletedNCT00175812Phase 1/2
- Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) ImageStatus unknownNCT00172562
- Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"Status unknownNCT00155844
- WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)Status unknownNCT00153582Phase 2
- Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous LeukemiaTerminatedNCT00152594Phase 3
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151255Phase 3
- Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151242Phase 2/3
- Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First RemissionTerminatedNCT00150878Phase 3
- Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2Status unknownNCT00149162Phase 3
- Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic ResultCompletedNCT00146120Phase 3
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
- High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
- Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
- Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
- Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2
- Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT00129948Phase 2
- Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00129168Phase 1/2
- Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)Status unknownNCT00126321Phase 2
- Clofarabine in Adult Patients With Advanced Solid TumorsCompletedNCT00125840Phase 1
- Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00124644Phase 1
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous LeukemiaCompletedNCT00116467Phase 2
- Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)CompletedNCT00114764Phase 2
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00112853Phase 1
- Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00112554Phase 3
- Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsStatus unknownNCT00111345Phase 2/3